BIOGEN INC (BIIB:NASDAQ)
$252.26 1.57 (0.6263%)
Analysed BIOGEN INC (BIIB:NASDAQ) News Sources
Biogen’s Quarterly Earnings Preview: What You Need to Know
13-10-2026
barchart.com
Biogen-backed Estuary nabs $93M for kidney disease gene therapy
16-10-2026
biopharmadive.com
A kidney transplant milestone has Wall Street excited about Biogen
17-10-2026
thestreet.com
Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
19-10-2026
yahoo.com
The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics
21-10-2026
yahoo.com
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
21-10-2026
yahoo.com
Biogen +5% on BofA Price Target Hike Ahead of “Relatively Quiet” Q3
22-10-2026
tikr.com
Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?
23-10-2026
yahoo.com
Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?
26-10-2026
yahoo.com
Kos Biotechnology Partners Announces Strategic Investment in Golden Age Health to Accelerate Global Access to Rare Disease Therapies
26-10-2026
yahoo.com
What is the current price of BIOGEN INC (BIIB:NASDAQ)?
The current price of BIOGEN INC (BIIB:NASDAQ) is $252.26.
BIOGEN INC (BIIB:NASDAQ) absolute price change since previous trading day?
The absolute price change of BIOGEN INC (BIIB:NASDAQ) since the previous trading day is $1.57.
BIOGEN INC (BIIB:NASDAQ) percentage price change since previous trading day?
The percentage price change of BIOGEN INC (BIIB:NASDAQ) since the previous trading day is 0.6263%.
What is the most recent average sentiment score for BIOGEN INC (BIIB:NASDAQ)?
The most recent average sentiment score for BIOGEN INC (BIIB:NASDAQ) is 85 out of 100.
What is the most recent average sentiment for BIOGEN INC (BIIB:NASDAQ)?
The most recent sentiment for BIOGEN INC (BIIB:NASDAQ) is .
SEC-8K** Filing Available For BIOGEN INC (BIIB:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.